Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Valneva cuts full-year outlook on lower COVID-19 vaccine sales

Stock Markets Aug 11, 2022 02:35AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Valneva logo and stock graph are seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) -French vaccine developer Valneva on Thursday cut its full-year revenue outlook citing lower demand for its anti-COVID shot from European Union member states.

The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes.

The French drugmaker, based in southwest France, now expects to post revenue for the year of between 340 million and 360 million euros ($370 million) down from an earlier forecast of 430 million to 590 million.

Its COVID-19 product sales should reach between 30 million euros and 40 million euros in 2022. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales.

In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.

"Given the revised volume of orders from the EU member states, we are evaluating how to reshape our operations," CEO Thomas Lingelbach said in a statement.

Further development of the current or potential second-generation COVID-19 vaccine will depend on funding or commitments the group receives in the third quarter, the company said.

It will aim to deploy about eight to 10 million doses of remaining inventory into international markets, as it expects the vaccine's shelf life to be gradually extended to at least 24 months.

Valneva expects sales of its travel-related products such as IXIARO for treating encephalitis or Dukoral for treating travellers' diarrhoea to reach 70 million to 80 million euros this year and demand may even exceed its current supply capacity as the market recovers faster than expected.

($1 = 0.9732 euros)

Valneva cuts full-year outlook on lower COVID-19 vaccine sales
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email